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A B S T R A C T
Herein is described the case of a 64-year-old patient affected by metastatic clear-cell car-
cinoma, with exclusive bone disease, subjected after the initial cytoreductive nephrectomy
to 3 successive lines of medical treatment (sunitinib, everolimus, and sorafenib) and mul-
tiple locoregional treatments (spinal surgery, radiation therapy, and selective arterial
embolization), resulting in a surprisingly long survival of over 75 months. In the era of target
therapy, integration strategies, including additional locoregional treatment to medical therapy,
are essential to optimize the clinical benefit, to maximize treatment duration overcoming
focal progressive disease, and to improve the quality of life. In this context, we would high-
light that selective transcatheter embolization of bone metastases from renal cell carcinoma
should be considered as an effective and safe option in the palliative setting for patients
with bone metastasis, especially for pain relief.
© 2017 the Authors. Published by Elsevier Inc. under copyright license from the University
ofWashington. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Renal cell carcinoma (RCC) represents 3% of all cancers, with
the highest incidence occurring in western countries and rep-
resenting the seventh most common cancer in men and the
ninth most common cancer in women [1]. Approximately 30%
of all patients with RCC havemetastatic disease at presentation,
and distantmetastases occurmost often in the lungs, the lymph
nodes, the liver, the bones, and the brain. In particular, lung
metastases affect 45%-50% of patients with advanced disease,
followed by bone (30%) and liver (20%) metastases [2]. The es-
timated average 5-year survival in metastatic renal cancer is
approximately 20% [3].
Bone metastases represent a crucial point in patient man-
agement because of the significant morbidity related to skeletal
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complications, such as pathologic fracture, spinal cord com-
pression, and hypercalcemia, and correlate with a poor
prognosis and a reduced overall survival [3,4].
The recent advances in our understanding of the patho-
genesis and the molecular landscape of renal cancer, and in
particular of clear-cell carcinoma, have led to the develop-
ment of molecular therapies targeting the vascular endothelial
growth factor and the mammalian target of rapamycin (mTOR)
pathways, and of immunotherapy resulting in a significant im-
provement of treatment options, rates of survival, and quality
of life [5]. The introduction of these new drugs revolutionized
the clinical management of patients affected by RCC with more
attention to the early clinical and imaging predictive factors
of treatment efficacy, with a more accurate management of the
side effects, and with a systematic and critical attitude on the
treatment sequence [5–8].
In addition to these varied scenarios of systemic ap-
proach, the locoregional treatments should be placed, with the
aim of controlling disease symptoms and optimizing system-
ic therapies, expanding the duration of each therapeutic line
and improving the quality of life.
Preoperative and palliative transarterial selective emboli-
zation is a safe and effective minimally invasive, interventional
treatment for pain relief and devascularization of primary and
metastatic bone tumors by various primary cancers [9–15].This
treatment can also be repeated during the course of disease
and can be combined with other treatment modalities such
as radiotherapy and chemotherapy.
Here we present the case of a patient affected by meta-
static RCC managed with a multimodality approach,
consecutively treated, for over 6 years, with 3 tyrosine kinase
inhibitors and several local treatments, including surgery, ra-
diotherapy, and, in particular, with two superselective arterial
embolizations of bone metastases, one in the right femur bone
and one in the right pubic region.
Case presentation
In April 2008, a 63-year-old man with a smoking habit and hy-
pertension, and overweight in personal medical history
presented with cruralgia and an intermittent pain in the left
lumbar region.The subject underwent a contrast-enhanced com-
puted tomography (CT) scan study,which demonstrated a large
infiltrativemass in the lower pole of the left kidneymeasuring
5.7 × 5.6 × 6.0 cm, with vertebral metastasis (D9-L3) and with
D12 and L1 cord compression and a right iliac crest metasta-
sis.Admission laboratory tests revealed a normocytic anemia,
amildly elevatedwhite cell count,and an elevated platelet count
(Hg of 8.9 g/dL, MCV 87 fL, white blood cell count 12,000/µL,
platelet count 573,000/µL). Chemistry laboratories revealed an
elevated lactate dehydrogenase (584 U/L) with normal kidney
and liver functions.Abonebiopsywasperformed,and thepatho-
logic examination revealed a metastasis by clear-cell RCC.
The patient underwent, in the first instance, a left
cytoreductive nephrectomy, followed by a surgical spinal de-
compression (D12 and L1) and stabilization (D9-L3) to avoid bone
complications and a radiation treatment of the back-lumbar
spine (D9-L3) with 20 Gy in 5 fractions for pain control.
After surgery, a first-line treatmentwith sunitinib as the first-
line therapy at a dose of 50 mg/day in a 4/2 schedule and
zoledronic acid was started. Under sunitinib treatment,which
was well tolerated, the patient had a progression-free survival
of approximately 41 months, higher than the median
progression-free survival observed in clinical trials [16–18]. A
CT scan performed after the sixth cycle of sunitinib docu-
mented an increase in the diameter of the metastatic lesion
localized in the right iliac crest associatedwith osteolytic aspects
and thenewappearance of a right femoral osteolyticmetastasis.
Radiotherapy of the right iliac crest (30 Gy in 10 fractions)
was performed for pain control, and an mTOR inhibitor was
started as a second-line therapy. Between April 2012 and No-
vember 2013, the patient was administered everolimus at a dose
of 10 mg/day, obtaining a surprisingly stable disease for about
19 months.After 6 months of everolimus treatment, the patient
experienced an interstitial pneumonitis, which required drug
discontinuation for 20 days, therapy with supplemental oxygen,
b-agonists, and prednisone 0.5 mg/kg.
In July 2013, during everolimus treatment, there was a sig-
nificant clinical progression of the disease with worsening of
the painful symptomatology in the right femur, with poor re-
sponse to opioid analgesics. A fluorine-18 fluorodeoxyglucose-
positron emission tomography scan showed hypermetabolic
lesions in the right femoral neck (SUVmax = 4.5) and the
omolateral pubic bone (SUVmax = 9) (Fig. 1).
With the aim of improving pain control and delaying the
occurrence of local complications, such as pathologic frac-
tures, an arterial embolization treatment was proposed. The
angiography, realized by microcatheter insertion into the
common femoral artery, showed the presence of 2 hypervascular
metastases in these 2 regions. The femoral and pubic lesions,
characterized by a rich and pathologic neovascularization
(Fig. 2), were embolized using N-butyl-cyanoacrylate with pal-
liative intent, obtaining a complete devascularization, with the
postembolization angiography showing a complete occlusion
of the pathologic feeding vessels (Fig. 3). Moreover, a signifi-
cant reduction in the pain score and the need for analgesics
were observed.
In June 2014, because of a further skeletal disease progres-
sion, a third-line therapy with sorafenib was started, at a
standard dose of 800 mg/day. After a 2-cycle occurrence of G2
anemia, G2 thrombocytopenia, fatigue, and G2 hand-foot syn-
drome required a dose reduction to 400 mg/day. In December
2014, because of a severe deterioration of the performance
status and disease progression, the cancer treatment was sus-
pended, directing the patient only to supportive care.
Discussion
Before 2005, kidney cancer was considered amalignancy orphan
of effective therapies, but in the past 10 years, the treatment
options have been greatly expanded.The discovery of the crucial
role of angiogenesis and the approval of sorafenib and sunitinib,
respectively, in 2005 and 2006 dramatically changed the clin-
ical outcome in these patients. In the following years, several
other therapeutic options, characterized by a high rate of disease
control, were approved, including vascular endothelial growth
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factor and vascular endothelial growth factor receptor
multikinase inhibitors (bevacizumab, pazopanib, axitinib,
cabozantinib, and lenvatinib), 2 mTOR inhibitors (everolimus
and temsirolimus), and,more recently, the immune checkpoint
inhibitor nivolumab [5]. Together with systemic therapies, a
multimodality approach integrating locoregional treatments
(surgery, radiotherapy, and arterial embolization) also repeat-
ed over the patient’s history, is currently increasing.
Fig. 1 – Pre-embolization axial computed tomography (A, C) and positron emission tomography (B, D) images showing
metastatic lesions and a pathologic fluorine-18 fluorodeoxyglucose uptake in the right pubic bone (SUVmax = 9) (A, B) and
in the right femoral neck (SUVmax = 4.5) (C, D). The red arrows in A and B indicate the pubic metastatic lesion, whereas the
red arrows in C and D indicate the right femoral neck metastatic lesion. SUV, stands for standardized uptake value.
Fig. 2 – Pre-embolization angiography. Two hypervascularized lesions: one in the proximal femur and one in the pubic bone.
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We report a case of a patient with bone metastases from
renal cancer locally treated with superselective arterial
embolizations of 2 hypervascular bone lesions for pain man-
agement. The patient experienced a clinical benefit with pain
control for 6 months and continued the same systemic therapy,
thus avoiding to replace a treatment still potentially effective
against the highest portion of disease.
All literature data regarding the use of the arterial emboli-
zation for the treatment of bone metastasis are retrospective;
further prospective studies are needed to better define the real
effectiveness of this treatment and the ideal setting to use.The
current main indications for arterial embolization are (1) a first-
line treatment of aneurysmal bone cyst as an alternative to
traditional surgery [19]; (2) a definitive treatment of benign lesions
such as hemangiomas or arteriovenous malformations; (3) a
primary or an adjuvant treatment such as surgery, radiation
therapy, or chemotherapy of both benign andmalignant lesions
to reduce bleeding before surgery and to facilitate other thera-
pies; and (4) a palliative treatment of skeletal metastases [11–15].
The procedure, performed under local anesthesia, con-
sists of a hyperselective catheterization through femoral artery
and embolization of the pathologic vessels feeding the lesion,
and is preceded by a diagnostic angiography to determine the
vascular mapping of the tumor [13].
Multiple embolic agents are currently available (polyvinyl
alcohol particles, gelatin sponge,N-butyl-cyanoacrylate, etc.).Many
factors determine the best choice of embolic material, such as
the duration of occlusive effect and the preservation of normal
tissue, but the most important is operator experience [14,20].
The main effects of the procedure are devascularization and
pain palliation.Vessel occlusion decreases the blood flow, the
edema, and the volume of the tumor, with a consequent re-
duction of periosteum distention and of pressure effects on
adjacent structures and nerves, resulting in pain relief, which
may last between 1 and 9 months; at this time, re-embolization
is safe and may be necessary. Complications of embolization
include dissection of the femoral artery, accidental emboliza-
tion of adjacent nontargeted vessels, subcutaneous or
muscle necrosis, infection caused by tissue ischemia, and
postembolization syndrome, characterized by fever and pain
caused by tumor necrosis [21].
The effectiveness of the procedure also depends on the spe-
cific histologic type, with a higher rate of successful treatment
in hypervascular metastases, such as in renal or thyroid lesions
[11,12,15].
In RCC, bone metastases are present in 30%-40% of the pa-
tients and are a major cause of morbidity, resulting in pain,
decreased mobility, and pathologic fracture. Palliative treat-
ment options for patients with bonemetastases are limited, such
as standard radiation therapy, if possible, and analgesic medical
treatments for pain control starting (nonsteroidal anti-
inflammatory drugs or opioids); the lead role is played by
radiation therapy, which, however, has limitations related to the
cumulative regional dose delivered and the consequent
inability to reradiate the same area. In one of the first
published experiences on arterial embolization of bone metas-
tasis from RCC, a retrospective review of 21 patients was
performed [22]. Thirty separate embolizations to treat 39
Fig. 3 – Postembolization angiography. Disappearance of the vasculature of the lesions.
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metastatic lesions obtained a clinical response (pain relief) in 36
treated sites; themean duration of the response was 5.5months.
More recently, a larger retrospective analysis was con-
ducted on 107 patients with bonemetastases from RCC [15]. One
hundred sixty-three embolizations using N-2-butyl cyanoacry-
late were performed from December 2002 to January 2011. The
mean tumor diameter before embolization was 8.8 cm. After a
mean follow-up of 4 years, a clinical response was achieved in
157 (96%) embolizations of sacroiliac metastases, and the mean
maximal tumor diameter after embolization was 4.0 cm. The
mean duration of the clinical response was 10 months (range
1-12). Moreover, hypoattenuating areas on the CT scan, resem-
bling tumor necrosis, were observed in all patients (mean 75%).
The most common complications (25% of the cases) were tran-
sient paresthesias in the lower extremities after embolizations
of the pelvis and sacrum metastatic lesions; all patients com-
pletely recovered within a week. These data suggest that
embolization may represent a rational therapeutic approach for
pain relief as an important and efficacious adjunct in manag-
ing patients with hypervascular RCC bone metastases.
The case herein described surprisingly achieved a long sur-
vival (75 months after diagnosis, despite a bone metastasis
generally correlated with a poor prognosis), thanks to the long
disease control obtained by systemic therapies (41 months with
sunitinib and 19 months with everolimus, respectively; prac-
tically a “super-responder” to everolimus) and the multiplicity
of locoregional approaches carried out, including arterial em-
bolization, which is a nonconventional procedure not currently
indicated in the international guidelines of RCC.Therefore, this
procedure should be considered in selected cases for the sig-
nificant clinical benefit that it can bring to patients.
The progressively better survival of patients with meta-
static RCC requires clinicians to use an increasing number of
therapeutic tools aimed at symptom control and improvement
of quality of life also in patients with a generalized metastatic
disease with multiple metastases in several sites. Selective
transcatheter embolization of bonemetastases from renal cancer
represents a reasonable tool for symptom palliation.
In conclusion, transcatheter arterial embolization does not
represent a standard treatment in bone metastasis manage-
ment but, in our case, brought significant clinical benefits,
especially in terms of a long-lasting pain relief in both treated
lesions and in the absence of embolization-related complications.
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